Malignant Heme Flashcards
Bleomycin (cytotoxic chemo)
Mechanism: inhibit DNA synthesis
Indication: HL
AEs: lung toxicity, pneumonitis, cytopenias
Cyclophosphamide (cytotoxic chemo)
Mechanism: alkylating agent that crosslinks DNA strands
Indication: ALL, NHL, myeloma, stem cell transplant, immunosupressant
AEs: neuropathy, AML, hemorrhagic cystitis, cytopenias, hair loss, GI
Doxorubicin (cytotoxic chemo)
Mechanism: anthracycline that inhibits topo II
Indications; AML, ALL, NHL, HL
AEs: cardiac failure, neuropathy, MDS, AML, cytopenias, hair loss, GI
Etoposide (cytotoxic chemo)
Mechanism: inhibit topo II
Indications: small cell lung cancer, testicular cancer, HL, NHL
AEs: neuropathy, MDS, AML, cytopenias, hair loss, GI
Hydroxyurea (cytotoxic chemo)
Mechanism: antimetabolite and stops ribonucleotides to convert to deoxyribo
Indications: myeloproliferatie neoplasms and sickle cell
AEs: macrocytosis, mucocutaneous lesions/ulcers
L-asparaginase (cytotoxic chemo)
Mechanism: cause leukemia cell apoptosis
Indication: ALL
AEs: thrombosis, liver failure, hypersensitivity
Methotrexate (cytotoxic chemo)
Mechanism: folate analogue that inhibits DNA synthesis
Indication: ALL, NHL, CNS lymphoma, autoimmune diseases
AEs: lots
Vinka alkaloids (cytotoxic chemo)
Mechanism: inhibit microtubule formation
Indication: HL, NHL, ALL, sarcoma, testicular cancer
AEs: neuropathy and constipation
ATRA (targeted chemo)
Mechanism: induce differentiation of promyelocytes
Indication: APL
AEs: fever, respiratory failure, fluid overload, multi-organ failure
Venetoclax (targeted chemo)
Mechanism: BCL-2 inhibitor
Indication: CLL, AML
AEs: cytopenias
Ibrutinib (targeted chemo)
Mechanism: BTK inhibitor
Indication: CLL, NHL
AEs: cytopenias, afib, bleeding
Imatinib (targeted chemo)
Mechanism: 1st gen BCR-Abl TK inhibitor
Indication: CML, ALL
AEs: fluid retention and GI upset
Dasatinib and nilotinib (targeted chemo)
Mechanism: 2nd gen BCR-Abl TK inhibitor
Indication: CML, ALL
AEs: D causes pleural effusions and N causes Qt prolongation
Ruxolitinib (targeted chemo)
Mechanism: JAK inhibitor
Indication: Myelofibrosis, PV
AEs: cytopenias
Lenalidomide
Mechanism: enhance T cell and NK cell mediated cytotox and direct tox for myeloma cells
Indication: myeloma and MDS
AEs: cytopenias and thrombosis